FindTrial
Sign In

Clinical Study of 68Ga Pentixafor PET/MR Imaging in the Qualitative and Lateral Diagnosis of Adrenal Functional Adenoma

Clinical Study of 68Ga Pentixafor PET/MR Imaging in the Qualitative and Lateral Diagnosis of Adrenal Functional Adenoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065247
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal functional adenoma

Interventions

Gold Standard:Pathological biopsy
Index test:68Ga-pentixafor PET/MR

Sponsors

Xijing hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients suspected of adrenal adenoma, but the PET/MR imaging of 68Ga-DOTA-NOC can not accurately identify and determine the side (the maximum difference of bilateral SUV is less than 30%).

Exclusion criteria

Exclusion criteria: Those who have surgical contraindications and cannot obtain postoperative pathology, pregnant women, lactating women, those who have evidence of severe impairment of liver and kidney functions, and those who have a history of allergy to nuclear medicine imaging agents or radiocontrast agents.

Design outcomes

Primary

MeasureTime frame
SUVmax;Focus size;aldosterone;Cortisol;—

Countries

China

Contacts

Public ContactFei Kang

Xijing hospital

fmmukf@qq.com+86 029 84775584

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026